Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma

Phase 3

• Conditions: Cervical Carcinoma
• Interventions: Drug: Endostar; Drug: DDP

• Registration Number: NCT03086681
• Lead Sponsor: Yong Zhang,MD

Brief Summary

A total of 120 patients with pathologically confirmed Locally advanced cervical carcinoma were enrolled. Patients were randomly divided into two groups, with 60 patients in each group. One group was treated with Concurrent Chemoradiotherapy combined with Endostar and the other group was treated with Concurrent Chemoradiotherapy. The short term efficacy and the toxic of these treatments were evaluated. The 1-year, 3-year, 5-year overall survival and progression-free survival of patients were analyzed. The investigators data may provide an alternative option for the treatment of Locally advanced cervical carcinoma with high efficacy and low toxicity.

Detailed Description

This study was a multicenter, randomized controlled clinical trial. A set of unified standards were used, including the clinical research program, inclusion criteria, exclusion criteria, chemoradiotherapy regimen and evaluation criteria. Nine medical centers participated in this study and 120 patients with pathologically confirmed Locally advanced cervical carcinoma were enrolled. These patients were randomly divided into two groups: concurrent chemoradiotherapy combined with Endostar group ( IMRT 45-50Gy, DDP 40mg/m2, per week for 5cycles, Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles) and concurrent chemoradiotherapy group ( IMRT 45-50Gy, DDP 40mg/m2, per week, for 5cycles). After treatment, follow-up was performed every 3 months. The treatment toxicity, local control rate, distant metastasis-free survival, overall survival, progression-free survival were observed and assessed.

Study Timeline

• Status Verified: 2017-03
• Study Start: 2017-03
• Study First Submitted: 2017-03-16
• Study First Submitted QC: 2017-03-16
• Last Update Submitted: 2017-03-16
• Study First Posted: 2017-03-22
• Last Update Posted: 2017-03-22
• Primary Completion: 2020-02
• Study Completion: 2020-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 120

Inclusion Criteria

• patients of either gender and aged from 18 to 65 years old.
• patients with histologically confirmed cervical carcinoma.
• patients at stage Ib, IIa2, IIb-IVa by FIGO 2009 staging.
• KPS ≥ 70 (Appendix I)
• patients with available MRI or CT data of cervical and measurable tumor lesions.
• patients did not receive any treatment before enrollment.
• patients with expected survival longer than 6 months.
• biochemical indexes: WBC > 4,000/mm3, and blood platelet ≥ 100,000 mm3; PT≤UNL; levels of indicators for hepatic and renal function was 1.5 folds of the upper limit of normal value.
• the informed content was obtained from every patient.
• patients with effective follow-up.

Exclusion Criteria

• those with malignant tumors other than cervical carcinoma.
• those received treatments before enrollmment.
• lactating women and Pregnant woman.
• those who were undergoing other drug trials.
• those with severe complications, including myocardial infarction, severe arrhythmia, severe cerebrovascular disease, ulcer disease, mental illness and uncontrollable diabetes.
• those who were treated with tumor targeting drugs.
• those who could not subject to MRI or CT examination.
• those who could not meet the requirements of the prescribed dose.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
concurrent chemoradiotherapy + endostar	Endostar	4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy
concurrent chemoradiotherapy + endostar	DDP	4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy
concurrent chemoradiotherapy	DDP	5 cycles of DDP concurrent with radiotherapy

Primary Outcome Measures

Name	Time	Method
short-time effect	3 months	3 months after treatment, the subjects go into observation period. MRI/CT will be used for evaluating the carcinoma status.

Secondary Outcome Measures

Name	Time	Method
Overall Survival	3 years,5 years	OS was calculated from the date of entry into the study to the date of death or the last follow-up visit.
Progression-Free Survival	3 years,5 years	PFS was calculated from the date of entry into the study to the date of first physical or radio-graphic evidence of disease progression, death or the last follow-up visit.

Trial Locations

Locations (1)

First Affiliated Hospital of Guangxi Medical University; 🇨🇳 Nanning, Guangxi, China